Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Senior Analyst at iREIT Forbes and Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, and Fox Business. He was the #1 contributing analyst on Seeking Alpha in 2014 (as ranked by TipRanks) and he is currently writing a book on the legendary investor Donald Trump.
Thomas has co-authored a book (The Intelligent REIT Investor) that is available on Amazon.
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College where he played basketball. He resides in South Carolina with his wife and kids.
Black Coral Research, Inc. is a newsletter designed to inform Dividend Investors how the latest news could impact the dividends of the companies they invest in. Feel free to contact us at BlackCoralResearch@gmail.com
To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 4 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
I am a market enthusiast and part-time trader. I started writing for Seeking Alpha in 2011, and it has been a tremendous opportunity and learning experience. I have been interested in the markets since elementary school, and hope to pursue a career in the investment management industry. I have been active in the markets for several years, and am primarily focused on long/short equities.
I hold a Bachelor of Science Degree from Lehigh University, where I double majored in Finance and Accounting, with a minor in History. My major track focused on Investments and Financial Analysis. While at Lehigh, I was the Head Portfolio Manager of the Investment Management Group, a student group that manages three portfolios, one long/short and two long only. I have had two internships, one a summer internship at a large bank, and another helping to manage the Lehigh University Endowment for nearly a year.
Disclaimer: Bill reminds investors to always due their own due diligence on any investment, and to consult their own financial adviser or representative when necessary. Any material provided is intended as general information only, and should not be considered or relied upon as a formal investment recommendation.
Disclosure: I'm not a financial adviser. All articles are my opinion - they are not suggestions to buy or sell any securities. Perform your own due diligence and consult a financial professional before trading.
Small business owner and investor. I've been involved with investing dating back to when I opened my first account at Olde Discount Brokers back in 1998 before it was purchased by H&R Block. My area of focus and ability is in value investing. I short commodities more often than I short stocks as I prefer to be a stocktimist or stock optimist by nature. I've only recently decided to become a contributor on the site as I'd like to share my research with others to help them with investing.
Founder, CEO and managing director of Vailshire Capital Management, LLC, in Colorado Springs.
Managing director of Vailshire Partners, LP: a multi-strategy "two-pronged" hedge fund seeking present value, future growth, and current income through an active safe options strategy. The fund frequently sells covered calls and naked puts to earn generous income and profit from market volatility. As a physician, a strong emphasis is placed on health care, pharmaceutical and biotech equities.
Retired on June 30, 2015 from practicing medicine as a Diagnostic and Interventional Radiologist in Colorado Springs, CO.
Currently a full-time investment professional, managing Vailshire Partners, 30+ separately managed accounts via Vailshire Capital Management, as well as, working as an "emerging manager" for a fund-of-funds based in New York.
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) firstname.lastname@example.org.
I analyze novel biotech ideas that I think can grow into healthy financial returns. I have over eighteen years of clinical trial experience as a clinical oncology pharmacist. My expertise is in cancer research but I have been evaluating drugs and drug therapies in all disease states for nearly two decades. In addition, I have an MBA in finance. I combine this knowledge with my pharmacy background to seek out companies that are coming of age. I believe that with each new idea comes an opportunity for profit.
I evaluate a company’s potential for growth by focusing on their science foremost and then I review their financials to determine how much investment risk is necessary to produce a return to the investor.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Old school investment analysis by 30 year stock market veteran Stan Barton.
The past editor of STOCK ACTION advisory letter and past coordinator of the MENSA investment group is now helping successful people develop and preserve their legacy at Barton Legacy Advisor, LLC.
For a free consultation contact him at www.bartonla.com
Owner and operator of: www.biostockselite.com Have over 15 years of investment experience and interest is dedicated to small cap biotech stocks. Articles submitted to SeekingAlpha will also be posted to my aforementioned site.
Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is an alias that I've used for years on Yahoo so I use it when I write on SA. I have gained a significant amount of knowledge regarding the stem cell sector over the years and have recently launched a premium service covering this exciting area.
Chief Market Strategist at www.buysellshort.net. Learn how to make a living trading small and midcap stocks
Additional Disclaimer: I may buy and sell any positions mentioned in any article at any time.
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
Gotham City Capital is a private, biotech research company. Our main objective is to provide investors with low-risk, high reward biotech investments and trades. We place the utmost emphasis on small cap bios that specialize in the most promising therapies out there. In our articles, we will aim to be very specific in our strategy, whether it be a catalyst run-up trade, swing trade or long-term investment. We strive to offer consistent opportunities for investors to create high returns on our biotech picks.
With approximately six year of studies, we feel that we have an excellent balance of expertise between trading, company financing, company management and most specifically, trial data. A solid track record of successfully finding the best trades and companies has driven us to start this company. We believe in making decent size bets on the best companies.
For real time market commentary, make sure to follow Gotham City Capital on Twitter.
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
I have been occasionally investing, as my personal time and money permit, via long positions over the course of 10 years. I don't work for a brokerage firm, and I'm not a professional trader. My interest has been predominantly within the biotechnology and energy sectors.
I'm a CPA licensed in Maryland. I have Bachelor degrees in both Accounting and Finance.
Stock Twits - http://stocktwits.com/Bio_Bull
Twitter - https://twitter.com/Bio_Bull_SA
I work in the medical and healthcare field so my focus is mainly on Biotech stocks. I try to find the next Celgene, the next Pharamcylics if possible.
Been a trader and investor for 13 years.
Love the game, and I hope you enjoy my articles on here.
Good luck with your investments and I look forward to all of your comments and suggestions.
Read more here
I have a Bachelors Degree In Business Administration. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks.
I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com and in addition I post stock market news on my other website Wallstreetrain.com
I have been a professional writer for over 20 years. I also have enjoyed searching micro and nano cap companies looking for hidden gems. Having grown up around stock brokers and commodities traders I have seen the business from both sides. I have been an investor in the market for most of my life.